Research programme: inflammatory disease therapeutics - AstraZeneca

Drug Profile

Research programme: inflammatory disease therapeutics - AstraZeneca

Alternative Names: AZ 10397767; CXCR2/CCR2b antagonists - AstraZeneca

Latest Information Update: 28 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Pyrimidinones; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 28 Feb 2011 No development reported - Preclinical for Asthma in United Kingdom (PO)
  • 28 Feb 2011 No development reported - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 28 Feb 2011 No development reported - Preclinical for Psoriasis in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top